SCYNEXIS Inc (DE:135)

NASDAQ:135

135

SCYNEXIS

RESEARCH TOOLSreports

SCYNEXIS (135) Price & Analysis

1 Followers

135 Stock Chart & Stats

€0.64

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.64

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€3.82 - €7.86

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

€36.22M

Enterprise Value€891.29K

Total Cash (Recent Filing)€59.26M

Total Debt (Recent Filing)€2.06M

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Aug 17, 2026

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.58

Shares Outstanding9,930,329

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.64

Price to Sales (P/S)1.53

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€27.59

Price Target Upside4211.15% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-2.57

Revenue Forecast (FY)€1.00M

Bulls Say, Bears Say

Bulls Say

Pipeline Expansion — SCY-770 AcquisitionAcquiring SCY-770 adds a Phase 2–ready, orphan-designated asset with an FDA-endorsed surrogate endpoint and IP to 2042. This materially diversifies the company beyond antifungals into a durable, high-value rare-disease market and supports a clear development path (Phase 2 planned), improving portfolio optionality and long-term commercial upside.

Improved Funding RunwayThe $40M PIPE materially extends funding visibility to mid-2029, lowering near-term dilution pressure and enabling planned Phase 2 initiation for SCY-770. A multi-year runway improves the company's ability to execute clinical milestones and negotiate partnerships without immediate capital raises, strengthening strategic optionality.

Conservative Balance-sheet LeverageRelatively low debt and conservative leverage provide financial flexibility to fund R&D or absorb development setbacks. With limited leverage, management has room to invest in clinical programs or pursue collaborations without acute solvency risk, supporting operational continuity over the medium term.

Bears Say

Ongoing Negative Cash FlowPersistent negative operating and free cash flow means the company cannot yet self-fund development and remains dependent on external financing. Over a multi-quarter horizon, continued cash burn raises dilution risk and could constrain program timing or force trade-offs between assets if cash consumption outpaces raised capital.

Earnings Volatility And Recent LossesSharp swings from prior profitability to steep losses indicate earnings instability and low margin durability. This volatility suggests revenue sources are lumpy and that operating leverage can rapidly amplify downturns, complicating long-term planning and raising the bar for consistent profitability absent structural revenue improvements.

Revenue Dependency On Partnerships/milestonesA business model weighted toward milestone and royalty income creates lumpy, timing-dependent revenue that can obscure underlying demand for products. Heavy reliance on partners for commercialization reduces direct control over market execution and can delay sustainable revenue scaling, making earnings and cash flow less predictable.

135 FAQ

What was SCYNEXIS Inc’s price range in the past 12 months?

SCYNEXIS Inc lowest stock price was €3.82 and its highest was €7.86 in the past 12 months.

What is SCYNEXIS Inc’s market cap?

SCYNEXIS Inc’s market cap is €36.22M.

When is SCYNEXIS Inc’s upcoming earnings report date?

SCYNEXIS Inc’s upcoming earnings report date is Aug 17, 2026 which is in 62 days.

How were SCYNEXIS Inc’s earnings last quarter?

Currently, no data Available

Is SCYNEXIS Inc overvalued?

According to Wall Street analysts SCYNEXIS Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SCYNEXIS Inc pay dividends?

SCYNEXIS Inc does not currently pay dividends.

What is SCYNEXIS Inc’s EPS estimate?

SCYNEXIS Inc’s EPS estimate is -0.44.

How many shares outstanding does SCYNEXIS Inc have?

SCYNEXIS Inc has 9,930,329 shares outstanding.

What happened to SCYNEXIS Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of SCYNEXIS Inc?

Currently, no hedge funds are holding shares in DE:135

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SCYNEXIS Stock Smart Score

Underperform

Analyst Consensus

Moderate Buy

Average Price Target:
€27.59 (4211.15% Upside)

Technicals

Fundamentals

Return on Equity

-57.16%

Trailing 12-Months

Asset Growth

14.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SCYNEXIS Inc

SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC). Furthermore, SCYNEXIS is progressing ibrexafungerp, its leading drug candidate, as both an oral and intravenous medicine designed to address various fungal conditions, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and challenging refractory invasive fungal infections. Ibrexafungerp has successfully completed the Phase 3 CANDLE study, which evaluated its effectiveness in preventing recurrent VVC. SCYNEXIS has also established collaborative research and commercialization agreements for ibrexafungerp with partners such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. Founded in 1999, the company is headquartered in Jersey City, New Jersey, and changed its name from SCYNEXIS Chemistry & Automation, Inc. to its current designation in June 2002.

135 Stock 12 Month Forecast

Average Price Target

€27.59

▲(4211.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","28":"€28","9.25":"€9.25","15.5":"€15.5","21.75":"€21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27.59134464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€27.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.59134464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.59134464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€27.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.25,15.5,21.75,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.5,6.276257279999999,8.052514559999999,9.82877184,11.60502912,13.381286399999999,15.15754368,16.93380096,18.71005824,20.486315519999998,22.262572799999997,24.038830079999997,25.81508736,{"y":27.59134464,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.5,6.276257279999999,8.052514559999999,9.82877184,11.60502912,13.381286399999999,15.15754368,16.93380096,18.71005824,20.486315519999998,22.262572799999997,24.038830079999997,25.81508736,{"y":27.59134464,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.5,6.276257279999999,8.052514559999999,9.82877184,11.60502912,13.381286399999999,15.15754368,16.93380096,18.71005824,20.486315519999998,22.262572799999997,24.038830079999997,25.81508736,{"y":27.59134464,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.968,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.472,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.704,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.528,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.352,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.528,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.592,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.128,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.032,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.016,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.24,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >